The Operating Theatre Journal - Flipbook - Page 19
British Infection Association 26th Annual Clinical and Scienti昀椀c Meeting
with Spring Trainee Day 2024
7-8 May 2024 | Event Website: https://昀椀twise.eventsair.com/2024-bia-spring-scienti昀椀c-meeting-and-trainee-day/
The two-day event will be held at the Mercure Bristol Grand Hotel and is aimed at specialists in infection, as well
as trainees, including microbiology, virology, clinical infectious diseases, public health, antimicrobial pharmacists,
biomedical scientists and infection prevention and control practitioners.
The trainee day will take place on Tuesday 7 May and the Scienti昀椀c meeting will be on Wednesday 8 May - all are
welcome at both days. The Programme will be available shortly.
For registration visit:
https://昀椀twise.eventsair.com/2024-bia-spring-scienti昀椀c-meeting-and-trainee-day/registration-and-fees
Abstract submissions are invited for oral and poster presentations.
The closing date for abstracts is 26 February 2024.
Visit: https://昀椀twise.eventsair.com/2024-bia-spring-scienti昀椀c-meeting-and-trainee-day/abstracts
to submit your abstract and 昀椀nd out more.
If you have any questions, please call the events team on 01506 292 042 or email: events@昀椀twise.co.uk
Lucida Medical, University of Cambridge and Hampshire Hospitals join forces to
develop Pi to transform the experience of patients living with prostate cancer
Cancer detection company Lucida Medical and leading doctors in
Cambridge and Hampshire launch a £1million project to develop
precision medicine technology to identify and manage the most
common cancer in men.
The analysis of multiple MRI scans is a time-consuming task for expert
radiologists, of whom there are too few in the UK. We are excited to be
able to develop cutting edge tools to offer patients and clinical teams a
smarter approach to active surveillance through this project.”
Lucida Medical, the University of Cambridge and Hampshire Hospitals
NHS Foundation Trust have been awarded funding by Innovate UK and
the Of昀椀ce for Life Sciences to extend the ground-breaking Pi software
platform to multiple clinical indications. Already certi昀椀ed to support
cancer diagnosis, this £1million programme will enable Pi to be used
throughout a patient’s journey with prostate cancer, enabling more
accurate and less invasive testing by using arti昀椀cial intelligence (AI) to
combine insights from MRI and clinical tests.
Research by Lucida Medical and by the University of Cambridge has
demonstrated how to predict whether prostate cancer is signi昀椀cant,
and track its evolution, more accurately by using AI methods. In this
programme, Hampshire Hospitals NHS Foundation Trust will lead the
development of a new dataset of patients on active surveillance. Lucida
Medical will use this to train new AI algorithms and develop additional
work昀氀ows to extend the Pi platform. The University of Cambridge will
then evaluate the Pi platform with data from prostate cancer patients
dating back over the last 10 years.
Over 50,000 men each year are diagnosed with prostate cancer in
the UK each year, and 490,000 live with or have been treated for the
disease. 1.4 million men are diagnosed annually worldwide. While
prostate cancer may initially develop slowly, it can be deadly if found
too late, killing more than 12,000 in the UK and 375,000 worldwide
each year.
This project will extend the Pi platform to further support active
surveillance of patients living with prostate cancer.
Dr Tristan Barrett, Associate Professor of Radiology at the University
of Cambridge, said: “in our clinical work, we offer active surveillance
to patients with lower risk prostate cancer, with regular imaging and
blood tests to track the cancer. The aim is to delay surgery or other
therapies that can have serious side-effects. We have shown this to be
a safe approach, which enables most men to retain their quality of live
for many years.”
Dr Aarti Shah, Consultant Radiologist at Hampshire Hospitals NHS
Foundation Trust, added: “monitoring patients on active surveillance
involves regular MRI scans, blood tests and occasionally biopsies.
The programme costs are covered by Lucida Medical with support from
Innovate UK’s Advancing Precision Medicine programme, including
funding from the Of昀椀ce of Life Sciences.
“With this collaboration, Pi will enable us to test and monitor cancer
patients using precision medicine across the whole prostate cancer
pathway. This will reduce the impact of the disease for both patients
and hospitals, and help ensure patients receive treatment exactly when
they need it,” commented Dr Antony Rix, CEO and co-founder of Lucida
Medical.
Lucida Medical will demonstrate Pi at the 2024 European Congress of
Radiology, where Dr Rix will present the results of the latest research
on the Pi platform in session RPS 605 on 28 February from 16:30.
Pi is available for use in the UK and EU
to support the diagnosis of prostate
cancer.
https://lucidamedical.com/
Find out more 02921 680068 • e-mail admin@lawrand.com
Issue 401
February
2024
19